Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced its participation in two upcoming virtual fireside chats at major biotechnology conferences on June 22, 2021.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/15/2021 - 07:00 AM EDT

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats at the LifeSci Genetics Medicine Conference and LSX Biotech Growth CEO Forum.

Conferences Details:

Event:			LifeSci Genetics Medicine Conference
Date:			Tuesday, June 22, 2021
Time:			10:00 am ET
Format:			Fireside chat
Participants:			RA Session II, President, Founder and CEO
			Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
			Kamran Alam, Chief Financial Officer

Event:			LSX Biotech Growth CEO Forum
Topic:			“Too Much of a Good Thing Can be Wonderful: Optimizing Value From Broad Discovery Platforms Through Strategy and Strategic Partnering”
Date:			Tuesday, June 22, 2021
Time:			1:10 pm ET
Format:			Fireside chat
Participants:			RA Session II, President, Founder and CEO

Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.